P. Hilgard

发表

PROSTACYCLIN DEFICIENCY IN THROMBOTIC THROMBOCYTOPENIC PURPURA

G. Mufti, J. Webster, P. Lewis, 1979, The Lancet.

Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies.

D. Leibfritz, H. M. Sonawat, J. Engel, 1990, Biochimica et biophysica acta.

Aspirin and tumour metastasis.

S. Wood, P. Hilgard, 1972, Lancet.

Microangiopathic Haemolytic Anaemia and Experimental Tumour‐Cell Emboli

E. Gordon-Smith, P. Hilgard, 1974, British journal of haematology.

Microangiopathic hemolytic anemia and experimental tumor-cell emboli

P. Hilgard, 1973 .

D-19575—a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport

M. Wiessler, J. Pohl, M. Nowrousian, 2009, Cancer Chemotherapy and Pharmacology.

Basis and new developments in the field of oxazaphosphorines.

H. Sindermann, N. Brock, P. Hilgard, 1988, Cancer investigation.

Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.

P. Hilgard, J. Pohl, J. Stekar, 1989, Arzneimittel-Forschung.

Microangiopathic haemolytic anaemia in cancer patients with bone marrow infiltration

P. Hilgard, Dr. N. Firusian, G. Faidas, 1978, Zeitschrift für Krebsforschung und Klinische Onkologie.

Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation.

M. K. Sykes, M. Chakrabarti, P. Hilgard, 1975, British journal of anaesthesia.

Bone marrow purging with mafosfamide — A critical survey

H. Sindermann, P. Hilgard, M. Peukert, 1989, Blut.

Immunological reactions to blood and blood products.

P. Hilgard, 1979, British journal of anaesthesia.

The antitumor activity of the platinum complex D-17872 is associated with tumor cell differentiation

R. Voegeli, J. Pohl, P. Hilgard, 2004, Cancer Chemotherapy and Pharmacology.

Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models

R. Voegeli, J. Pohl, P. Hilgard, 2004, Cancer Immunology, Immunotherapy.

Ifosfamide--current aspects and perspectives.

W. Brade, K. Herdrich, P. Hilgard, 1983, Cancer treatment reviews.

Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.

M. Mareel, G. Storme, D. L. Van den Berge, 1993, European journal of cancer.

Experimental hypercalcaemia and whole blood clotting

P. Hilgard, P. HILGARD', N. Stratton, 1973, Journal of clinical pathology.

Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133

R. Voegeli, J. Engel, P. Hilgard, 2004, Cancer Chemotherapy and Pharmacology.

Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide.

T. Klenner, P. Hilgard, J. Stekar, 1995, European journal of cancer.

Antiinvasive activity of hexadecylphosphocholine in vitro.

M. Mareel, E. Bruyneel, G. Storme, 1991, Anticancer research.

Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.

C. Unger, H. Eibl, J. Engel, 1989, Acta oncologica.

Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).

C. Unger, M. Berger, H. Eibl, 1988, European journal of cancer & clinical oncology.

Alkylphosphocholines: a new class of membrane-active anticancer agents

C. Unger, T. Klenner, P. Hilgard, 2004, Cancer Chemotherapy and Pharmacology.

Monoclonal cryoglobulin of IgG (λ) type interacting with transferrin

O. Wetter, P. Hilgard, K. H. Linder, 1981, Blut.

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

H. Sindermann, C. Unger, H. Eibl, 1990, Progress in experimental tumor research.

Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.

H. Sindermann, C. Unger, H. Eibl, 1988, Onkologie.

Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols

S. Orrenius, N. Brock, J. Pohl, 2004, Journal of Cancer Research and Clinical Oncology.

Anticoagulants in the treatment of cancer.

P. Hilgard, R. Thornes, 1976, European journal of cancer.

The development of alkylphosphocholines as signal transduction inhibitors: experimental and clinical challenges

J. Engel, P. Hilgard, J. Pohl, 2005, Journal of Cancer Research and Clinical Oncology.

The Role of Blood Platelets in Experimental Metastases

P. Hilgard, 1973, British Journal of Cancer.

Oxazaphosphorine toxicity reduction by mesna.

P. Hilgard, J. Pohl, 1990, Cancer treatment reviews.

Mechanism of lung tumour colony reduction caused by coumarin anticoagulation.

B. Maat, P. Hilgard, 1979, European journal of cancer.

The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL)

C. Schmidt, P. Hilgard, H. Heller, 1976, Zeitschrift für Krebsforschung und Klinische Onkologie.

Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems

B. Maat, P. Hilgard, 2004, Journal of Cancer Research and Clinical Oncology.

Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL).

C. Schmidt, G. Schmitt, P. Hilgard, 1977, British Journal of Cancer.

Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone.

K. Voigt, T. Klenner, G. Mcgregor, 1996, European journal of cancer.

Fibrinolysis, thromboplastin activity and localization of radioiodinated fibrinogen in experimental tumors.

P. Hilgard, V. Hiemeyer, 1970, European journal of cancer.

Heparin treatment of microangiopathic haemolytic anaemia associated with an experimental tumour.

P. Hilgard, H. Heyes, W. Köhle, 1982, Thrombosis research.

Mechanisms of C. Parvum-induced coagulopathy in mice.

J. Castro, P. Hilgard, H. Mitcheson, 1980, British Journal of Cancer.

Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives.

R. Voegeli, P. Hilgard, J. Pohl, 1985, Cancer treatment reviews.

Investigation into the immunological effects of miltefosine, a new anticancer agent under development

P. Hilgard, L. Nolan, T. Reissmann, 2005, Journal of Cancer Research and Clinical Oncology.

Gene Trapping Identifies Inhibitors of Oncogenic Transformation

H. von Melchner, T. Beckers, P. Hilgard, 1998, The Journal of Biological Chemistry.

alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.

P. Hilgard, M. Peukert, J. Pohl, 1984, Cancer treatment reviews.

Induction of the c-myc but not the cH-ras promoter by platinum compounds.

D. Kerr, A. Eliopoulos, P. Hilgard, 1995, Biochemical pharmacology.

Short communication: Cause and prevention of mafosfamide-induced venous pain

J. Pohl, P. Hilgard, 2004, Investigational New Drugs.

The use of RA 233 in the preparation of platelets, with the blood cell separator

P. Hilgard, J. Beyer, 1977, Blut.

Coagulation studies in the BNML rat leukaemia

P. Hilgard, 1977 .

Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone

J. Harleman, P. Hilgard, A. Comaru-Schally, 2005, Journal of Cancer Research and Clinical Oncology.

The effect of heparin on the initial phase of metastasis formation.

P. Hilgard, M. Kübler, L. Beyerle, 1972, European journal of cancer.

Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression

R. Voegeli, P. Hilgard, T. Reissmann, 2004, Journal of Cancer Research and Clinical Oncology.

Platelet shape change abnormalities in diabetic retinopathy

E. Kohner, M. Porta, P. Hilgard, 1980, Diabetologia.

Thrombin-induced Disseminated Intravascular Coagulation. Ill: Modification by Dextran Infusion

M. K. Sykes, M. Chakrabarti, P. Hilgard, 2022 .

SYNTHESIS OF PROCOAGULANT ANTIHÆMOPHILIC FACTOR IN VITRO

P. Hilgard, D. Mohanty, 1979, The Lancet.

Pulmonary vasoconstriction produced by protamine and protamine-heparin complex in the isolated cat lung perfused with blood or dextran.

M. K. Sykes, P. Hilgard, J. Jastrzębski, 1975, Cardiovascular research.

Mafosfamide — A Derivative of 4-Hydroxycyclophosphamide

H. Sindermann, J. Engel, J. Pohl, 1989 .

Current status of oxazaphosphorine analogue development.

P. Hilgard, 1987, Cancer treatment reviews.

Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.

M. Przybylski, N. Brock, P. Hilgard, 1985, Biomedical mass spectrometry.

Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors

P. Hilgard, G. Atassi, J. Pohl, 2004, Investigational New Drugs.

Experimental toxicology of ASTA Z 7557 (INN mafosfamide)

P. Hilgard, H. Zechel, W. Jahn, 2004, Investigational New Drugs.

Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation

R. Voegeli, P. Hilgard, T. Reissmann, 1986 .

Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.

P. Hilgard, H. Burkert, 1984, European journal of cancer & clinical oncology.

[Hypercalcemic activity of Walker carcinosarcoma 256 in the rat].

R. Ziegler, H. Minne, P. Hilgard, 1971, Schweizerische medizinische Wochenschrift.

CANCER AND VITAMIN K

P. Hilgard, 1977, The Lancet.

Experimental vitamin K deficiency and spontaneous metastases.

P. Hilgard, 1977, British Journal of Cancer.

Induction of disseminated intravascular coagulation by endotoxin and saline loading in rats II. Fibrin deposition and removal.

W. Theiss, P. Hilgard, H. Heyes, 1975, Thrombosis research.

Induction of disseminated intravascular coagulation by endotoxin and saline loading in rats. I. The influence on fibrinogen turnover and plasma parameters.

W. Theiss, P. Hilgard, H. Heyes, 1975, Thrombosis research.

Microangiopathic Haemolytic Anaemia Associated with Hypercakaemia in an Experimental Rat Tumour

P. Hilgard, R. Hohage, W. Köhle, 1973, British journal of haematology.

[Intravascular coagulation in solid Walker carcinosarcoma 256].

R. Ziegler, H. Minne, P. Hilgard, 1971, Schweizerische medizinische Wochenschrift.

Acute hypercalcemia due to Walker carcinosarcoma 256 in the rat.

R. Ziegler, H. Minne, P. Hilgard, 1970, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Trial of oral miltefosine for visceral leishmaniasis

S. Sundar, H. Murray, M. Makharia, 1998, The Lancet.

Hexadecylphosphocholine: determination of serum concentrations in rats.

C. Unger, H. Eibl, P. Hilgard, 1991, Journal of lipid mediators.

Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening.

P. Hilgard, H. Maurer, 1992, Progress in experimental tumor research.

D-21266, a new heterocyclic alkylphospholipid with antitumour activity.

J. Engel, T. Klenner, J. Engel, 1997, European journal of cancer.

Etoposide--chemistry, preclinical and clinical pharmacology.

N. Niederle, P. Hilgard, W. Achterrath, 1982, Cancer treatment reviews.

Current development of podophyllotoxins

L. Lenaz, R. Canetta, P. Hilgard, 2004, Cancer Chemotherapy and Pharmacology.

Experimental therapeutic studies with miltefosine in rats and mice.

R. Voegeli, J. Harleman, P. Hilgard, 1992, Progress in experimental tumor research.

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

H. Sindermann, C. Unger, H. Eibl, 1990, Cancer treatment reviews.

Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.

H. Sindermann, C. Unger, H. Eibl, 1988, Onkologie.

Blood platelets and tumour dissemination.

P. Hilgard, 1982, Progress in clinical and biological research.

Alkylphosphocholines : new drugs in cancer therapy

C. Unger, H. Eibl, P. Hilgard, 1992 .

The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity.

P. Hilgard, M. Iselt, W. Holtei, 1989, Arzneimittel-Forschung.

Activation of fibrinolysis by a lymphogenic activator in the rat.

P. Hilgard, R. Hohage, 1972, Lymphology.

D-19466, a new cyclobutane-platinum complex with antitumor activity

R. Voegeli, P. Hilgard, J. Respondek, 2005, Journal of Cancer Research and Clinical Oncology.

Low-dose heparin in the management of acute myelocytic leukaemia

M. Nowrousian, P. Hilgard, 1978, Blut.

Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XVI: Cytostatic and cytotoxic side effects of oligoamines

P. Hilgard, K. Rehse, R. Maurer, 1991, Archiv der Pharmazie.

[Separation and pharmaco-toxicological studies of the enantiomers of Ifosfamide].

G. Blaschke, J. Maibaum, P. Hilgard, 1986, Arzneimittel-Forschung.

New pharmaceuticals: miltefosine.

P. Hilgard, 1990, Anti-cancer drugs.

Hypercalcemia and clotting.

P. Hilgard, 1970, The New England journal of medicine.

Thrombin-induced disseminated intravascular coagulation in the dog. I: Demonstration of microthrombi in lung.

M. K. Sykes, P. Hilgard, J. Jastrzębski, 1975, British journal of anaesthesia.

Critical Analysis of Experimental Models for the Antimetastatic Effects of Anticoagulants

B. Maat, P. Hilgard, 1980 .

Lymphatic fibrinolysis in rats

P. Hilgard, V. Hiemeyer, R. Hohage, 1971, Experientia.

Estrophilic cisplatin derivatives

J. Engel, P. Hilgard, H. Schönenberger, 1987 .

Heterocyclic alkylphospholipids with an improved therapeutic range.

T. Klenner, J. Engel, P. Hilgard, 1996, Advances in Experimental Medicine and Biology.

Anticoagulants and tumor growth: pharmacological considerations.

P. Hilgard, 1983, Symposium on Fundamental Cancer Research.

Coagulant and Fibrinolytic Activities of a Metastasising and A Non-Metastasising Tumour Line

P. Alexander, P. Hilgard, D. Mohanty, 1990, Thrombosis and Haemostasis.

A New Platelet Aggregating Material (PAM) in an Experimentally Induced Rat Fibrosarcoma

P. Hilgard, D. Mohanty, 1984, Thrombosis and Haemostasis.